(VERA) Vera Therapeutics - Overview
Stock: Atacicept, MAU868, VT-109
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 73.8% |
| Relative Tail Risk | -14.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.54 |
| Alpha | -4.69 |
| Character TTM | |
|---|---|
| Beta | 1.276 |
| Beta Downside | 0.631 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.09% |
| CAGR/Max DD | 1.30 |
Description: VERA Vera Therapeutics January 14, 2026
Vera Therapeutics, Inc. (NASDAQ: VERA) is a clinical-stage biotechnology firm developing immunology-focused therapies. Its lead candidate, atacicept-a fully humanized TACI-Fc fusion protein that simultaneously blocks BAFF and APRIL-is being tested as a sub-cutaneous, at-home treatment for immunoglobulin A nephropathy (IgAN). The pipeline also includes MAU868, a monoclonal antibody that completed a Phase 2 trial for BK virus viremia, and VT-109, a dual BAFF/APRIL inhibitor targeting B-cell-mediated autoimmune disorders. The company, originally incorporated in 2016 as Trucode Gene Repair, rebranded to Vera Therapeutics in April 2020 and is headquartered in Brisbane, California.
Key recent metrics: as of the latest 10-Q (Q3 2024), Vera reported cash and cash equivalents of approximately $45 million, giving it a runway into 2026 assuming current burn rates. In its Phase 2 IgAN study, atacicept achieved a ~30% relative reduction in 24-hour proteinuria versus placebo, a clinically meaningful signal that aligns with the estimated $2 billion U.S. market for IgAN therapies. The broader biotech sector continues to benefit from a 7% YoY increase in R&D spending, driven by heightened investor appetite for niche immunology assets, which could support Vera’s ability to raise follow-on capital if needed.
For a deeper dive into VERA’s valuation metrics and peer comparisons, a quick look at ValueRay’s analyst toolkit can be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.41 > 0.02 and ΔFCF/TA -1.28 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.41 > 3% & CFO -210.3m > Net Income -251.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.8m) vs 12m ago 16.30% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.51%; Δ -0.51% > 0%) |
| Interest Coverage Ratio: -32.61 > 6 (EBITDA TTM -243.2m / Interest Expense TTM 7.50m) |
Altman Z'' -7.96
| A: 0.90 (Total Current Assets 506.2m - Total Current Liabilities 41.9m) / Total Assets 517.5m |
| B: -1.29 (Retained Earnings -669.8m / Total Assets 517.5m) |
| C: -0.55 (EBIT TTM -244.4m / Avg Total Assets 443.0m) |
| D: -5.64 (Book Value of Equity -668.8m / Total Liabilities 118.6m) |
| Altman-Z'' Score: -7.96 = D |
What is the price of VERA shares?
Over the past week, the price has changed by +0.55%, over one month by -6.49%, over three months by +72.48% and over the past year by +17.00%.
Is VERA a buy, sell or hold?
- StrongBuy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VERA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 75.2 | 72.8% |
| Analysts Target Price | 75.2 | 72.8% |
| ValueRay Target Price | 59.3 | 36.2% |
VERA Fundamental Data Overview February 01, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -244.4m USD
EBITDA TTM = -243.2m USD
Long Term Debt = 74.6m USD (from longTermDebt, last quarter)
Short Term Debt = 473.0k USD (from shortTermDebt, last quarter)
Debt = 77.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.65b USD (3.07b + Debt 77.2m - CCE 497.4m)
Interest Coverage Ratio = -32.61 (Ebit TTM -244.4m / Interest Expense TTM 7.50m)
EV/FCF = -12.54x (Enterprise Value 2.65b / FCF TTM -211.5m)
FCF Yield = -7.98% (FCF TTM -211.5m / Enterprise Value 2.65b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.13m) / Revenue TTM)
Tobins Q-Ratio = 5.12 (Enterprise Value 2.65b / Total Assets 517.5m)
Interest Expense / Debt = 2.54% (Interest Expense 1.96m / Debt 77.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -193.1m (EBIT -244.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.09 (Total Current Assets 506.2m / Total Current Liabilities 41.9m)
Debt / Equity = 0.19 (Debt 77.2m / totalStockholderEquity, last quarter 398.9m)
Debt / EBITDA = -0.08 (negative EBITDA) (Net Debt 19.4m / EBITDA -243.2m)
Debt / FCF = -0.09 (negative FCF - burning cash) (Net Debt 19.4m / FCF TTM -211.5m)
Total Stockholder Equity = 494.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.87% (Net Income -251.9m / Total Assets 517.5m)
RoE = -50.92% (Net Income TTM -251.9m / Total Stockholder Equity 494.8m)
RoCE = -42.92% (EBIT -244.4m / Capital Employed (Equity 494.8m + L.T.Debt 74.6m))
RoIC = -34.64% (negative operating profit) (NOPAT -193.1m / Invested Capital 557.5m)
WACC = 10.41% (E(3.07b)/V(3.15b) * Re(10.62%) + D(77.2m)/V(3.15b) * Rd(2.54%) * (1-Tc(0.21)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 42.72%
Fair Price DCF = unknown (Cash Flow -211.5m)
EPS Correlation: 4.28 | EPS CAGR: 22.53% | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.23 | Chg30d=+0.020 | Revisions Net=+2 | Analysts=6
EPS next Year (2026-12-31): EPS=-4.52 | Chg30d=+0.190 | Revisions Net=+4 | Growth EPS=-1.8% | Growth Revenue=+0.0%